119 results about "DIAGNOSTIC ANTIGENS" patented technology

A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.

The invention discloses gene orders of schistosoma japonicum recombinant multi-epitope antigens BSjGCP-BSj23 and BSjGCP-BSj23-BSj28, a method for expressing and purifying the same, and application thereof in preparing schistosomiasis japonica immunity prevention vaccines and diagnostic reagents. Recombinant multi-epitope nucleic acid vaccines pCMV-BSjGCP-BSj23 and pCMV-BSjGCP-BSj23-BSj28 obtain 14.76 percent and 64.95 percent of worm reduction rates respectively in Kunming mice. The recombinant multi-epitope antigens pGEX-BSjGCP-BSj23 and pGEX-BSjGCP-BSj23-BSj28 obtain 15.7 percent and 57.99 percent of worm reduction rates in immunizing BalB/c mice, and obtain 91.0 percent and 89.9 percent of sensitivities as well as 97.8 percent and 93.4 percent of specificities respectively as diagnostic antigens.

Provided herein is an in vitro granuloma model and methods of its use. Methods of detecting and/or diagnosing latent tuberculosis in a subject are also provided, as are latency-specific antigens (and antibodies thereto), such as alpha-crystallin, and methods of identifying and using such molecules. Also provided are immunostimulatory compositions, for instance for use in eliciting an immune response in a subject, such as an immune response to a latent tuberculosis infection. Kits for carrying out the provided methods are also described.

The invention provides a schistosoma japonicum katsurada recombinant protein SjSAPLP4 as well as encoding gene and application thereof. The protein has an amino acid sequence shown as SEQ ID NO.2 or an amino acid sequence having a same function, formed by replacing, omitting and/or adding one or more amino acid residues for the amino acid sequence shown as SEQ ID No.2. The invention also provides a gene sequence for encoding the protein. The recombinant protein SjSAPLP4 is good in immunogenicity, can be used as an excellent diagnostic antigen, can be used for preparing a schistosoma japonicum katsurada diagnosis kit having high sensitivity and high specificity, also can be used for preparing an anti-schistosome vaccine and can be used as a potential drug acting target spot to screen the drug for treating the schistosoma japonicum katsurada.

The invention relates to enterovirus 71 type specific recombinant protein antigen and application thereof. The amino acid sequence is shown as SEQIDNO. 1; and the nucleotide sequence is shown as SEQIDNO. 2. The recombinant protein can be applied in preparation of monoclonal antibodies and polyclonal antibodies as well as detection of enterovirus 71 type specific antibodies. The invention provides a novel diagnostic antigen for serological detection of enterovirus 71 type infection. Experiments show that the enterovirus 71 type specific recombinant protein antigen has good sensitivity and specificity, can be identified by human serum after the enterovirus 71 type infection and inactivated full-virus immune serum of animals, can be applied in serological diagnosis of the enterovirus 71 type infection, and can also be applied in vaccine development and evaluation of immune effects in use. Compared with the full-virus particles as diagnostic antigens, the specific protein antigen can be prepared easily, and the cost of kit preparation is reduced.

The invention relates to the prevention and treatment field of human papillomavirus infection, in particular to an amino acid modification sequence of recombinant human papillomavirus (HPV) L1 capsid protein, a nucleotide sequence encoding the amino acid modification sequence, and a carrier and a transformant containing the nucleotide sequence; and the invention further relates to application of an HPV L1 protein polymer consisting of the amino acid modification sequence to preparing vaccines, pharmaceutical compositions and diagnostic antigen or diagnostic antibodies. In the invention, an HPV L1 protein wild-type sequence is modified to prevent forming of a disulfide bond in the HPV L1 protein, the modification has no significant effect on the structural stability of the recombinant HPV L1 protein, but significantly improves the efficiency of purification process, and directly reduces the reagent consumption, thus effectively lowering the industrial production cost and having great economical benefit.

The invention aims at providing a simple and quick Zika virus detection kit. The kit optimally selects fusion expression protein as diagnostic antigen; an anti-human IgG monoclonal antibody A374, an anti-human IgM monoclonal antibody A371 and a biotin-BSA conjugate are respectively coated on a nitrocellulose membrane as a detection line and a quality control line; colloidal gold labeled fusion expression protein and colloidal gold labeled streptavidin and other reagents are matched; and an immunochromatography capture method principle is used for qualitative detection of Zika virus specific IgM antibody and IgG antibody in human serum, thereby realizing quick and specific diagnosis of Zika virus infection.

The invention discloses a theileria equi immunoblotting detecting method and a method for preparing a kit, wherein the theileria equi immunoblotting detecting method in the invention is established on the basis of acquiring diagnostic antigen and positive control serum via Cochlearia officinalis hyperoxide enzyme label and chemical light emitting prime. The solvent for the method in the inventionis little in amount, low in cost, high in specificity, high in sensitivity, high and fast in operation, free of toxicity and harm, low in required conditions, easy for judging the test result, long-time for storage, and stronger in specificity than ELISA. The method in the invention detects no false positive and false negative result.

The invention discloses a foot-and-mouth disease virus (FMDV) 2C3ABC recombinant protein as well as a preparation method and application thereof, and belongs to the field of pharmaceutical biotechnology. According to the invention, the mutation of the following sites is performed on the basis of an original FMDV 3C protease gene: Cys142-Ser, Cys163-Gly. FMDV recombinant protein 2C3ABC is expressed as an inclusion body in the bacterial cytoplasm, and is subjected to separation, denaturation, renaturation and multi-step purification, to obtain a complete and enzymolysis-free FMDV nonstructural protein mu2C3ABC, wherein the protein has solubility and complete antigenicity, and has a molecular weight of 72 kDa. The protein, as a diagnostic antigen, is prepared into chromatographic strips, has sensitivities of 98.4% and 100% respectively in the detection of FMDV experimentally infected pigs and naturally infection-free pigs, and has specificities of 100% and 98% respectively in the detection of naturally infection-free pigs and vaccine-immunized pigs. Compared with commercial kits Ceditest and UBI, the FMDV 2C3ABC recombinant protein has a high degree of consistency, can be used to distinguish infected animals and immunized animals, wherein K = 0.823 (p is smaller than 0.05).

The disclosed embodiments are generally directed to improving feature detection of rapidly acquired images using camera-enabled mobile devices involving a 2-D decal code, such as a QR code, for improving the reading accuracy of a rapid diagnostic antigen or antibody or enzymatic colorimetric directed test, such as for COVID-19 diagnosis. One primary issue with evaluating a Covid-19 rapid test is detecting and quantifying positive test lines from sampled test strips based on digital images of the test strip. Aspects of the present invention contemplate masking a QR code to improve the sample image resolution and contrast. Other aspects of the present invention contemplate methods and techniques to evaluate a test line on the sample image by enhancing an intensity curve along the test line and control line containing area by way of calculating the instantaneous change in pixel intensity and evaluating the position and intensity of those signals.

The invention discloses recombinant alpha protein for inhibiting clostridium perfringens infection and a preparation method and application thereof. The recombinant alpha protein is shown in (a) or (b) or (c), wherein the protein in (a) is composed of amino acid sequences shown as SEQ ID No.2; the protein in (b) is composed of amino acid sequences shown at the sites No.51-No.353 of SEQ ID No.2; the fusion protein in (c) is obtained by fusing protein tags at carboxyl terminals or/and amino terminals of the protein shown in (a) or (b). The recombinant alpha protein enables animals to have a higher serum antibody level and resist attack of clostridium perfringens after the animals are immunized with the recombinant alpha protein. The recombinant alpha protein is good in solubility and easy to purify and can serve as a diagnostic antigen to be prepared into a monoclonal antibody or be used for further research on protein functions and conformation relations.

The invention discloses a B19 virus VP1 unique region gene, and constructs a B19 procaryon to express pQE30-VP1 unique region of cloning plasmid, express and purify the recombinant protein; the recombinant protein can cause immune cells response in vitro, and produce the highly effective antibodies; the B19 virus recombination protein of the present invention can be used for antigen diagnosis and for preparing antibody and vaccine for prevention of B19 virus.

The invention discloses an establishment method of an animal model in mice infected with sparganosis mansoni, comprising the following steps: cleaning and soaking polypide taken out from the body of the animal naturally infected with sparganum mansoni with sterilized normal saline; injecting the polypide into the gullets of the healthy mice by the method for pouring belly for inoculation; after raising the inoculated mice for a period, transplanting the inoculated mice by the method for pouring belly, carrying out standard raising on the transplanted mice and carrying out one-time new rejuvenation transplantation and collection on the infected mice which are raised for a period within 3-12 months; and establishing the stable animal model in mice infected with sparganum mansoni. The method specifies the collection method of the sparganum mansoni species resources and the living body conservation operation technology, provides the stable disease animal model for the research on immunity characteristics, immunopathological injury, diagnosis and treatment of sparganosis mansoni and provides the standard species resources with stable biological characteristics for the scientific research, teaching, quarantine and diagnostic antigen production units.

The invention provides a schistosoma japonicum katsurada recombinant protein SjSAPLP5 as well as an encoding gene and an application thereof. The protein provided by the invention has amino acid sequence as shown in SEQ ID No.2 or has amino acid sequence which is formed by replacement, deletion and/or addition of one or more of amino acid residues and has the same function. The invention also provides the encoding gene for encoding the protein. The recombinant protein SjSAPLP5 provided by the invention is excellent in immunogenicity, can be served as an excellent diagnosis antigen, is used for preparing a schistosoma japonicum katsurada diagnostic kit with high sensitivity and high specificity, and is also used for preparing an anti-schistosome vaccine and the drug served as a potential drug effecting target spot and is used for screening and treating the schistosoma japonicum katsurada diseases.

The invention discloses an application of cellulase in soluable and secretion expression of recombinant protein in escherichia coli. The protein sequence is an amino acid sequence represented by SEQ ID NO: 1-7, or a polypeptide sequence having 70% or more homology with the amino acid sequence represented by SEQ ID NO: 1-7, and the recombinant protein is antibacterial peptides or enzymes. The application of cellulase in soluable and secretion expression of recombinant protein in escherichia coli provides a foundation for preparing protein/ polypeptide drugs, various enzymes, diagnostic antigens, antibodies, vaccines and the like by using escherichia coli, and has important theoretical meanings and application values in protein expression study, enzymic preparations, protein drug production and the like.

The invention relates to a method for purifying a recombinant protein of the gene engineering and aims to provide a method for purifying a recombinant VP1 antigen of enterovirus type 71 viruses. The method comprises the following steps of: expressing and producing a recombinant VP1 protein of the enterovirus type 71 viruses by Escherichia coli obtain an inclusion body of the protein; dissolving the inclusion body in solubilizing liquid; and dropwise adding the solution of the inclusion body into renaturation solution under the conditions of water bath and magnetic stirring and then carrying out stirring renaturation on the mixture for 48 hours. The invention discloses the method, which can make the protein existing in a form of the inclusion body become a soluble protein by protein renaturation so as to greatly improve recovery rate of an expression product. The method adopts affinity chromatography for purification in one step. The purity is over 95 percent. The method for purifying the recombinant VP1 antigen of the enterovirus type 71 viruses has simple, convenient and time-saving operation, is favorable for large-scale industrial production, has the advantages of low cost, simple and convenient process, high purity of the purified protein and the like and can provide the diagnostic antigen for development of an EV type 71 diagnostic reagent and seroepidemiological survey.

Compositions and methods for the detection of Taenia solium and the diagnosis of T. solium infection are described. The nucleotide and amino acid sequences of the antigenic T. solium polypeptides gp50a, gp50b and gp50c are provided. The compositions contain synthetic antigenic polypeptides of larval origin prepared using the sequences described herein. Probes and primers for the detection or amplification of T. solium nucleic acid molecules are also described. The polypeptides can be administered to a human or animal to protect against T. solium infection. In addition, the polypeptides are useful as research tools for studying T. solium and as reagents in assays for the detection of T. solium antibodies in a biological sample. The methods are sensitive and specific assays that utilize the stable recombinant or synthetic antigenic polypeptides or nucleic acid molecules encoding the larval polypeptides.

The invention discloses a babesia caballi disease immunoblotting detection method and a kit. The babesia caballi disease immunoblotting detection method is established on the basis of obtaining a diagnostic antigen and positive control serum through a goat anti horse second antibody compound marked by horse radish peroxidase and a chemiluminescence substrate. The method has the advantages of less reagent dosage, low cost, high specificity, high sensitivity, quicker operation, no toxicity and harm, low required condition, easy judgment of a test result, long-term storage and stronger specificity than ELISA (Enzyme-Linked Immuno Sorbent Assay). By detecting by using the method, false positive and false negative results are not detected.

The invention provides a pseudorabies virus GE protein and preparation of a colloidal-gold immunochromatographic strip thereof. The pseudorabies virus colloidal-gold immunochromatographic strip is provided with a carrier plate, a sample pad, a colloidal-gold conjugate pad, a laminate membrane, a detection line, a quality-control line and an absorption pad. The expressed recombinant protein existedin a supernatant is easy to purify. The detection method established by taking the recombinant protein, which is purified by affinity chromatography, as a diagnostic antigen is low in cost and simpleand convenient, and especially the diagnostic antigen concentrates major antigen-epitopes of the gE antigen. The detection sensitivity and specificity of the recombinant protein are both higher thanthe intact gE protein.